



## Centre for Tropical Medicine and Global Health

Nuffield Department of Medicine  
Nuffield Department of Medicine Research Building  
University of Oxford  
Old Road Campus, Roosevelt Drive  
Headington  
OXFORD  
OX3 7FZ

Cambridge East REC  
E-submission  
23 October 2023

Dear Dr Lamont

**Trial:** Randomised evaluation of Covid-19 therapy (RECOVERY)  
**EudraCT:** 2020-001113-21  
**IRAS:** 281712  
**REC ref:** 20/EE/0101  
**Amendment:** Substantial Amendment 33 (13-Sep-2023)

Please find enclosed an application for authorisation of a substantial amendment for the RECOVERY trial. This adds a new corticosteroid comparison for community-acquired pneumonia (CAP) caused by pathogens other than SAR-CoV-2 or influenza. CAP is usually caused by bacterial pathogens and is a common cause of hospital admission and death worldwide, but there is little robust evidence to guide treatment. In contrast to COVID-19, it is unclear whether corticosteroid treatment reduces mortality in CAP. As a platform trial for patients hospitalised with pneumonia, RECOVERY is ideally suited to provide robust evidence to inform the treatment of CAP in the same way that it has for COVID-19.

The current RECOVERY collaboration includes hospitals in six countries in Asia and Africa, as well as the UK, and this amendment also incorporates an expansion to EU countries, which we are planning to open this winter (France, Italy and the Netherlands). The following documents are attached:

- 1 Cover letter
- 2a,b. RECOVERY protocol V27.0 2023-09-13 (tracked and clean)
- 3a,b. RECOVERY PIS/ICF (adult) V26.0 2023-09-13(tracked and clean)
4. Justification addition of the corticosteroid comparison for CAP.
5. Amendment tool for SA33
6. Email confirming sponsor approval

Please let us know if you require any further information.

Yours faithfully

Professor Sir Peter W. Horby  
FRCP FFPH PhD FMedSci  
Chief Investigator, RECOVERY Trial  
Moh Family Foundation Professor of Emerging Infectious Diseases and Global Health